logo-loader
viewCytoDyn Inc.

CytoDyn says data from its Phase 2b/3 Vyrologix coronavirus trial will be made public, pending regulatory talks

The trial enrolled 394 severe-to-critical COVID-19 patients who were randomized to receive either 700 milligrams of Vyrologix or a placebo once a week by injection

Coronavirus graphic
Aside from COVID-19, the FDA has granted Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses

CytoDyn Inc (OTCQB:CYDY) announced Monday that study results have been unblinded from the CD12 trial of its drug Vyrologix (leronlimab or PRO-140) in coronavirus (COVID-19) patients, and the company will reveal them once discussions with regulators are complete.  

The Phase 2b/3 trial enrolled 394 severe-to-critical COVID-19 patients, who were randomized to receive either 700 milligrams of Vyrologix or a placebo once a week by injection. 

The primary outcome measured is linked to mortality at day 28, the company has said previously. There are secondary outcomes measured by mortality at day 14, change in clinical status at day 14, change in clinical status of the subject at day 28, and change from baseline in Sequential Organ Failure Assessment (SOFA) score at day 14. 

READ: CytoDyn partners with Chiral Pharma to register Vyrologix in the Philippines

“We are eager to reach [a] conclusion in our discussions with all the regulatory agencies for the path going forward and will release the details of our data and the results of our discussions with regulatory agencies in the coming weeks,” CEO Nader Pourhassan said in a statement.

CytoDyn previously completed a Phase 2 clinical trial for COVID-19, a double-blinded, clinical trial for mild-to-moderate patients in the US, which produced statistically significant results using the National Early Warning Score (NEWS2) degree of illness metric.

Aside from COVID-19 , the US Food and Drug Administration (FDA) has granted Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 2.91 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.74 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn achieves 75% enrollment for its severe-to-critical coronavirus...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC). Pourhassan says...

on 23/11/20

2 min read